액체생검 시장 : 바이오마커별, 검체별, 유형별, 기술별, 적응증별, 최종 사용자별, 용도별 시장 예측(2026-2032년)

The Liquid Biopsy Market is projected to grow by USD 17.31 billion at a CAGR of 12.63% by 2032.

Liquid Biopsy Executive Summary

Liquid biopsy is redefining precision oncology by enabling analysis of circulating tumor DNA, circulating tumor cells, cell-free DNA, RNA, methylation signatures, exosomes, and other analytes from blood or other body fluids. Unlike conventional tissue biopsy, liquid biopsy can support less invasive sampling, longitudinal monitoring, and faster molecular profiling when tissue is unavailable, insufficient, or difficult to access.

The field has moved from exploratory research to clinical utility, supported by U.S. FDA-authorized companion diagnostics, broad use of next-generation sequencing, and increasing guideline recognition in advanced cancers. Demand is strongest in therapy selection, resistance monitoring, minimal residual disease assessment, recurrence surveillance, and emerging multi-cancer early detection applications, where evidence quality, analytical sensitivity, and clinical validity remain decisive adoption factors.

Transformative Shifts in Liquid Biopsy

The liquid biopsy landscape is shifting from single-gene mutation testing toward broader multi-analyte, multi-omics platforms. Laboratories and diagnostics developers are combining ctDNA mutation profiling with methylation, fragmentomics, epigenomic signals, proteomics, and AI-enabled interpretation to improve sensitivity and clinical relevance across cancer stages.

Regulatory and reimbursement expectations are also transforming adoption. FDA-cleared and FDA-approved tests have strengthened physician confidence, while payers increasingly require evidence of clinical utility, outcome improvement, and cost-effectiveness. At the same time, decentralized blood collection, biopharma partnerships, and clinical trial stratification are expanding use beyond late-stage oncology into recurrence risk, treatment response, and screening, particularly in settings where repeat tissue biopsy is clinically impractical.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the impact of liquid biopsy by improving signal detection in low-abundance tumor fractions, reducing sequencing noise, and supporting interpretation of complex genomic and epigenomic patterns. Machine learning models are increasingly used for variant calling, methylation classification, tumor-origin prediction, and risk stratification, especially where early-stage disease produces limited ctDNA.

AI also supports operational scalability through automated quality control, bioinformatics workflow optimization, laboratory workflow prioritization, and clinical decision support. However, adoption depends on transparent validation, bias assessment across populations, data governance, cybersecurity, and compliance with evolving AI and medical device regulations. The most defensible AI-enabled liquid biopsy strategies are those anchored in prospective clinical evidence, reproducible model performance, and traceable analytical validation.

Key Regional Insights: Global Liquid Biopsy Adoption

North America remains a leading liquid biopsy region due to advanced oncology infrastructure, established molecular pathology networks, FDA regulatory pathways, major clinical trial activity, and payer engagement around companion diagnostics and genomic profiling. The United States anchors adoption through precision medicine programs, cancer center networks, and integration of liquid biopsy into oncology drug development, while Canada shows steady implementation through provincial oncology systems, centralized laboratory models, and evidence-based reimbursement review.

Europe is shaped by strong academic oncology, the EU In Vitro Diagnostic Regulation, and national health technology assessment processes that emphasize clinical validity, clinical utility, and quality management. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in genomic medicine, local sequencing capacity, cancer screening infrastructure, and advanced oncology care. Latin America is progressing through private-sector testing, reference-lab partnerships, and expanding molecular oncology awareness, while the Middle East is accelerating precision oncology through national transformation programs, advanced hospital systems, and investment in genomic medicine. Africa remains earlier in adoption, with opportunities centered on access, sample logistics, oncology workforce development, laboratory accreditation, and regional reference laboratories that can improve availability of liquid biopsy testing.

Key Group Insights: Strategic Liquid Biopsy Clusters

Within ASEAN, liquid biopsy demand is supported by rising cancer burden, medical tourism hubs, expanding private diagnostics networks, and improving access to oncology specialists, although reimbursement, laboratory standardization, and cross-country regulatory alignment remain uneven. The GCC is investing in precision medicine, population health, advanced oncology centers, and digital health infrastructure, creating favorable conditions for premium liquid biopsy services, localized validation, and partnerships with diagnostic providers and academic hospitals.

The European Union is defined by IVDR compliance, cross-border cancer research, quality assurance requirements, and evidence-led reimbursement, making analytical validation and demonstrated clinical utility essential for scale. BRICS countries are important growth engines because of large patient populations, local sequencing capabilities, government interest in biotechnology self-sufficiency, and expanding cancer care capacity. G7 markets lead in clinical trial adoption, regulatory sophistication, reimbursement scrutiny, and oncology guideline integration, while NATO countries benefit from overlapping healthcare modernization, biomedical research funding, laboratory interoperability initiatives, and secure data infrastructure that can strengthen genomic medicine and liquid biopsy implementation.

Key Country Insights: Priority Liquid Biopsy Markets

The United States leads commercialization through FDA-authorized assays, companion diagnostic use, oncology guideline adoption, and biopharma use in clinical trials. Canada is advancing through centralized cancer programs, provincial testing pathways, and evidence-based assessment, while Mexico and Brazil show growing private-lab adoption, reference laboratory partnerships, and increasing interest in expanding molecular oncology access. The United Kingdom, Germany, France, Italy, and Spain are building liquid biopsy use through national genomics strategies, cancer networks, molecular tumor boards, and health technology assessment discipline; Russia's market is shaped by domestic testing capacity, regional oncology infrastructure, and constrained access to some international technologies.

China is scaling local liquid biopsy innovation through high-volume oncology demand, domestic sequencing capacity, and regulatory attention to advanced diagnostics. India is expanding access through urban oncology centers, cost-sensitive laboratory models, and rising demand for precision cancer care. Japan and South Korea benefit from strong precision medicine ecosystems, regulatory maturity, advanced cancer care infrastructure, and active oncology research networks. Australia supports adoption through guideline-driven oncology practice, academic research, established molecular pathology networks, and structured evaluation of new diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with clear clinical utility, such as therapy selection in advanced cancer, resistance monitoring, and measurable residual disease programs backed by prospective evidence. Product roadmaps should align assay performance with intended use, including limits of detection, tumor fraction requirements, sample handling specifications, turnaround time, reporting clarity, and interpretability for oncologists.

Commercial success will depend on payer-ready evidence, regulatory-quality validation, laboratory accreditation, and partnerships with cancer centers, biopharma sponsors, and reference laboratories. Organizations should invest in interoperable bioinformatics, transparent AI governance, diverse clinical datasets, real-world evidence generation, and patient-friendly blood collection models. Regional strategies should be tailored to reimbursement maturity, oncology infrastructure, local regulatory requirements, and clinical workflow readiness rather than relying on one global commercialization template.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and industry-recognized sources. Inputs include regulatory databases and announcements from agencies such as the U.S. FDA and European authorities; clinical guidance from oncology organizations including NCCN, ASCO, and ESMO; peer-reviewed oncology and molecular diagnostics literature; clinical trial registries; reimbursement updates; public health datasets from sources such as WHO and OECD; and documented technology developments in next-generation sequencing, ctDNA analysis, methylation profiling, and AI-enabled bioinformatics.

Insights are triangulated across regulatory milestones, clinical adoption signals, technology trends, regional healthcare infrastructure, guideline evolution, reimbursement conditions, and peer-reviewed evidence. The analysis excludes unsupported market claims and emphasizes evidence-backed interpretation of liquid biopsy applications, including companion diagnostics, ctDNA profiling, minimal residual disease, recurrence monitoring, treatment response assessment, and early detection research.

Conclusion: Evidence-Led Growth in Liquid Biopsy

Liquid biopsy has become a central pillar of precision oncology because it offers a practical route to real-time molecular insight with lower procedural burden than tissue biopsy. Its strongest current value lies in therapy selection, resistance detection, and longitudinal monitoring, while early cancer detection and multi-cancer screening remain high-potential areas requiring rigorous validation, careful implementation, and clear evidence of clinical benefit.

The next phase of leadership will be defined by clinical evidence, regulatory credibility, AI-enabled analytical performance, reimbursement alignment, and equitable access. Organizations that combine scientifically validated assays with payer-aligned outcomes, regional execution, robust laboratory quality systems, and trustworthy data infrastructure will be best positioned to shape the future of liquid biopsy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liquid Biopsy Market, by Biomarkers

• 7.1. Cell-free DNA
• 7.2. Circulating Tumor Cells
• 7.3. Circulating Tumor DNA
• 7.4. Extracellular Vesicles

8. Liquid Biopsy Market, by Sample

• 8.1. Blood Based
• 8.2. Urine Based

9. Liquid Biopsy Market, by Type

• 9.1. Assay Kits
• 9.2. Instruments
• 9.3. Services

10. Liquid Biopsy Market, by Technology

• 10.1. Multi-gene Parallel Analysis using NGS
• 10.2. Single-gene Analysis using PCR Microarrays

11. Liquid Biopsy Market, by Indication

• 11.1. Cancer Indication
  • 11.1.1. Breast Cancer
  • 11.1.2. Colorectal Cancer
  • 11.1.3. Lung Cancer
  • 11.1.4. Melanoma
  • 11.1.5. Prostate Cancer
• 11.2. Non-Cancer Indication

12. Liquid Biopsy Market, by End-User

• 12.1. Academic & Research Centers
• 12.2. Clinical Diagnostic Laboratories
• 12.3. Hospitals
• 12.4. Physician's Office Laboratories

13. Liquid Biopsy Market, by Application

• 13.1. Early Cancer Screening
• 13.2. Recurrence Monitoring
• 13.3. Therapy Selection
• 13.4. Treatment Monitoring

14. Liquid Biopsy Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Liquid Biopsy Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Liquid Biopsy Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. ANGLE PLC
• 18.2. Bio-Rad Laboratories, Inc.
• 18.3. Bio-Techne Corporation
• 18.4. Biocartis NV
• 18.5. Danaher Corporation
• 18.6. DiaCarta, Inc.
• 18.7. Dxcover Limited
• 18.8. Epic Sciences Inc.
• 18.9. Exact Sciences Corporation
• 18.10. F. Hoffmann-La Roche Ltd.
• 18.11. GENCURIX
• 18.12. Guardant Health, Inc.
• 18.13. Illumina, Inc.
• 18.14. Labcorp Holdings Inc.
• 18.15. Laboratory Dr. med. Pachmann
• 18.16. Lucence Health Inc.
• 18.17. LungLife AI, Inc.
• 18.18. MDxHealth SA
• 18.19. Menarini Silicon Biosystems SpA
• 18.20. Merck KGaA
• 18.21. Myriad Genetics, Inc.
• 18.22. Natera, Inc.
• 18.23. NeoGenomics Laboratories, Inc.
• 18.24. OncoDNA SA
• 18.25. PerkinElmer, Inc.
• 18.26. Personalis, Inc.
• 18.27. QIAGEN N.V.
• 18.28. SAGA Diagnostics AB
• 18.29. Strand Life Sciences Pvt Ltd.
• 18.30. Sysmex Corporation
• 18.31. Tempus AI, Inc.
• 18.32. Thermo Fisher Scientific Inc.